In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers in Norway—a trend we expect to continue throughout 2025.
Development costs in Q4 2024 totaled nearly DKK 4 million, compared to DKK 4.4 million in Q4 2023. The decrease is mainly due to the higher costs in 2023, which included the final closing payment for our acquisition of Nimorazole. We remain focused on advancing the Rivelin patch, esketamine, and Gefena for the US market, as well as preparing for the planned registration filing of Nimorazole for Head and Neck Cancer in Q1 2026. We are committed to maintaining this focus and continuing our investment in new products throughout 2025.
EBITDA for Q4 2024, including R&D costs, amounted to DKK -0.9 million, compared to DKK -5.1 million in Q4 2023. Excluding R&D costs, EBITDA reached DKK 3 million in Q4 2024, up from DKK -0.7 million in Q4 2023.